gms | German Medical Science

55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

25. bis 28.04.2004, Köln

Diagnosis of recurrent gliomas: Positron emission tomography [18F]Fluor-O-Ethyl-Tyrosine versus MRI

Diagnose von Gliomrezidiven: [18F]Fluor-O-Ethyl-Tyrosin-Positronenemissionstomographie versus MRT

Meeting Abstract

  • corresponding author Walter Rachinger - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München
  • C. Goetz - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München
  • G. Pöpperl - Nuklearmedizinische Klinik, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München
  • M. Holtmannspötter - Neuroradiologische Klinik, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München
  • K. Tatsch - Nuklearmedizinische Klinik
  • J.-C. Tonn - Neurochirurgische Klinik, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München

Deutsche Gesellschaft für Neurochirurgie. Ungarische Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. DocMO.09.08

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dgnc2004/04dgnc0096.shtml

Published: April 23, 2004

© 2004 Rachinger et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective

Tumor recurrence appears in a large amount of patients suffering from glioma. Due to the variety of presently accessible modalities for treatment of gliomas, it has become more difficult to differentiate tumor recurrence from therapy associated contrast enhancement. In order to increase the diagnostic accuracy in the detection of tumor recurrence in glioma patients, we performed FET-PET in addition to MRI and compared the diagnostic value of these two modalities.

Methods

MRI findings of 45 multimodally treated glioma patients (1 pilocytic astrocytoma, 8 astrocytomas WHO grade II, 1 oligoastrocytoma WHO grade II, 1 oligodendroglioma WHO grade II, 11 anaplastic astrocytomas, 1 oligodendroglioma WHO grade III, and 22 glioblastoma multiforme WHO grade IV) were correlated with findings of FET-PET in these patients. Final diagnosis was verified by biopsies (21 patients) or clinical follow-up (24 patients).

Results

Sensitivity of FET-PET was 100%, specificity was 92,9%. The positive predictive value was 96,9%, the negative predictive value 100%. For MRI, sensitivity was 93,5%, specificity was 50%. The positive predictive value was 80,6%, the negative value was 77,8%.

Conclusions

Statistical analysis showed that in clinical follow-up of multimodally treated glioma patients discrimination between tumor recurrence and therapy associated contrast enhancement is not sufficient by MRI alone. More accurate diagnosis will be achieved by the additional performance of FET-PET examination in the clinical aftercare of these patients.